Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Georgios I Papageorgiou"'
Autor:
Georgios I. Papageorgiou, Evangelos Fergadis, Nikos Skouteris, Evridiki Christakos, Sergios A. Tsakatikas, Evangelos Lianos, Christos Kosmas
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Poly-ADP ribose polymerase (PARP) inhibitors are constantly increasing in their indications for use as anti-cancer treatment in various neoplasms, the majority of which are linked with BRCA deficiency. Preclinical data support the investigation of PA
Externí odkaz:
https://doaj.org/article/d0462d14688f4ca3bc41ba28ea0ba502
Autor:
Maria Tolia, Rodanthi Fioretzaki, Dimitrios Schizas, Christo Kole, Stylianos Kykalos, Sergios Tsakatikas, Georgios I Papageorgiou, Nikolaos Charalampakis
Publikováno v:
Immunotherapy. 13:1113-1134
Cholangiocarcinoma (CCA) is a rare malignancy with generally dismal prognosis. Immunotherapy has revolutionized the management of cancer patients during the last decade, offering durable responses with an acceptable safety profile, but there are stil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77b61906da0e2b4b890cd6bdbdd78fa0
https://doi.org/10.2217/imt-2021-0126
https://doi.org/10.2217/imt-2021-0126
Autor:
Marilita M Moschos, Konstantinos A A Douglas, Vivian Paraskevi Douglas, Sergios Tsakatikas, Christos Kosmas, Alexandros D Liatsos, Georgios I Papageorgiou, David G Symeonidis
Publikováno v:
Anti-Cancer Drugs. 32:1146-1149
Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor 2 (Her2) - targeted antibody-drug conjugate that is approved for patients previously treated with trastuzumab and a taxane for Her2-positive advanced breast cancer and those wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043f3a4e981b53264acca3e9e1f6f228
https://doi.org/10.1097/cad.0000000000001117
https://doi.org/10.1097/cad.0000000000001117
Publikováno v:
Anti-Cancer Drugs. 32:330-336
Glioblastoma multiforme is a malignant central nervous system (CNS) disease with dismal prognosis. Current treatment modalities only offer modest activity and usually of short duration, so there is an urgent need for the conduct of clinical trials ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6df610909b60990cb3c6bba522f54e56
https://doi.org/10.1097/cad.0000000000001021
https://doi.org/10.1097/cad.0000000000001021
Publikováno v:
JCO Oncology Practice. 16:155-162
CNS tumors are one of the most common causes of cancer-related death in the 15- to 39-year-old age group. The management of adolescents and young adults (AYAs) who are diagnosed with brain tumors presents unique endocrine, developmental, and psychoso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ccffa0e6a725b3c766201430eda24a9
https://doi.org/10.1200/jop.18.00767
https://doi.org/10.1200/jop.18.00767
Autor:
Christos Valavanis, Evridiki Christakos, Gabriela Stanc, Georgios I Papageorgiou, Christos Kosmas, Efthymia Souka, Aikaterini Filippakou, Sergios Tsakatikas, Evangelia Papantoni, Evangelos Fergadis, Nikos Skouteris
Publikováno v:
Anti-cancer drugs. 33(2)
Monoclonal antibodies against programmed cell death protein 1 (PD-1) and PD-1 ligand 1 (PD-L1) are the main representatives in the field of immunotherapy and their indications are constantly increasing in medical oncology and hematology during the la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::284d151544bef430452ca867f62609dc
https://pubmed.ncbi.nlm.nih.gov/34538865
https://pubmed.ncbi.nlm.nih.gov/34538865
Publikováno v:
Anti-cancer drugs. 32(3)
Glioblastoma multiforme is a malignant central nervous system (CNS) disease with dismal prognosis. Current treatment modalities only offer modest activity and usually of short duration, so there is an urgent need for the conduct of clinical trials ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fc2be0282c3e9eb8f7376368497d362b
https://pubmed.ncbi.nlm.nih.gov/33229903
https://pubmed.ncbi.nlm.nih.gov/33229903